Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sagimet Biosciences Inc. director Elizabeth A. Grammer received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.

The shares underlying this option are scheduled to vest in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. This is a compensation-related award and does not reflect any open-market buying or selling of Sagimet stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GRAMMER ELIZABETH A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,567	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 39,567 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 39,567 options Exercise price: $6.48 per share Expiration date: June 11, 2036 +2 more

5 metrics

Option grant size 39,567 options Stock Option grant to director Elizabeth A. Grammer

Exercise price $6.48 per share Exercise price of Series A Common Stock options

Expiration date June 11, 2036 Option term for director grant

Post-grant derivative holdings 39,567 options Total options held following the reported transaction

Vesting schedule 12 monthly installments Vests over twelve equal monthly installments after June 12, 2026

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "6.4800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:21 PM Accepted by SEC EDGAR 06/15/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAMMER ELIZABETH A

(Last)

(First)

(Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO

CALIFORNIA

94402

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.48	06/12/2026		A		39,567		⁽¹⁾	06/11/2036	Series A Common Stock	39,567	$0	39,567	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Sagimet Biosciences (SGMT) director Elizabeth Grammer report in this Form 4?

Elizabeth A. Grammer reported receiving a stock option grant for 39,567 shares of Sagimet Biosciences Series A Common Stock at a $6.48 exercise price, expiring June 11, 2036, as part of her director compensation package.

Is the Sagimet (SGMT) Form 4 a buy or sell of common stock?

The Form 4 does not show any open-market buy or sell. It reports a grant of stock options as compensation, giving the director the right to buy 39,567 shares at $6.48 per share in the future, subject to vesting.

How do the Sagimet Biosciences (SGMT) options granted to the director vest?

The options vest over twelve equal monthly installments following June 12, 2026. Each monthly tranche vests only if Elizabeth A. Grammer continues serving on the board on the applicable vesting date, aligning the award with ongoing service.

What is the exercise price and expiration date of the SGMT director stock options?

The stock options have a fixed exercise price of $6.48 per share and an expiration date of June 11, 2036. After expiration, any unexercised options will lapse and no longer give the right to purchase Sagimet Biosciences shares.

How many Sagimet (SGMT) options does the director hold after this transaction?

After this transaction, Elizabeth A. Grammer is shown holding 39,567 stock options directly. These options all relate to Series A Common Stock and are subject to the stated vesting schedule and the $6.48 per share exercise price.